Repligen Corporation
RGENHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. Valued at $11.23B, RGEN is a large-cap name in its sector. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Market Cap
$11.23B
Beta
1.08
P/E (TTM)
242.37
P/E (Fwd)
65.61
EPS (TTM)
$0.73
EPS (Fwd)
$2.70
ROE
2.0%
ROA
1.4%
Cash
$810.4M
Total Debt
$690.9M
Free CF
$113.4M
52W Change
9.8%
Annual Financials
Cash vs Debt
Where RGEN stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, RGEN finished 24.31% above its 150-day moving average ($140.67) and 21.64% above its 200-day moving average ($143.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RGEN overbought or oversold?
At the October 7, 2026 close, RGEN's RSI(14) was 51.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $810.4M in cash comfortably exceeding the $690.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $113.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $670.5M to $738.3M.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Repligen Corporation's trajectory.